Compare Grab Holdings Ltd. (GRAB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Organon & Co. Common Stock — how do they compare? Grab Holdings Ltd. trades at $2.9 (market cap $11.91B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Grab Holdings Ltd. is far larger — about 3.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Organon & Co. Common Stock for 0 Days on average.
| GRAB | OGN | |
|---|---|---|
Market Cap | $11.91B | $3.61B |
Volume | 62,622,940 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $6.12 | $13.81 |
52-Week Low | $2.80 | $5.70 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $7.64B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Grab Holdings trades at $2.98, down 5.4% amid bearish technical signals, though fundamentals show strong improvement with revenue growth to $3.37B in 2025 and a shift to profitability (net income $268M). Recent news highlights a $1.49B acquisition of Atome Financial and insider buying, contrasting with mixed market sentiment.
Outlook is cautiously optimistic: analyst consensus is 91.7% buy ratings, but risks include integration of acquisitions and regional competition. The stock's current price near recent lows may offer entry points for growth-focused investors, pending Q3 2026 earnings results.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
